Figure 1
(a) OS and (b) DFS of 60 patients with Ph+ALL who underwent allo-HSCT in their first CR following imatinib-based therapy.
Figure 1 | Blood Cancer Journal
(a) OS and (b) DFS of 60 patients with Ph+ALL who underwent allo-HSCT in their first CR following imatinib-based therapy.
